Drug Database
TR

trimethoprim hydrochloride (Primsol)

✓ Approved

Sun Pharmaceutical Industries Ltd. · Small Molecule · Small Molecule

What is trimethoprim hydrochloride?

trimethoprim hydrochloride is a small molecule developed by Sun Pharmaceutical Industries Ltd.. It is approved for therapeutic indications via oral (po).

Drug Profile

Brand NamesPrimsol
CompanySun Pharmaceutical Industries Ltd.
Drug ClassSmall Molecule
RouteOral (PO)
StatusApproved

Therapeutic Indications

trimethoprim hydrochloride is developed for 3 unique indications across 2 therapeutic areas.

Therapeutic AreaConditionPhase
Infections and infestationsOtitis media✓ Approved
Ear and labyrinth disordersMiddle ear inflammation✓ Approved
Infections and infestationsUrinary tract infection✓ Approved

Related Research Articles

PubMedFrontiers in immunology2026-10-15

Case Report: Multiple brain abscess-like lesions with concurrent detection of Nocardia amamiensis and Leishmania infantum in cerebrospinal fluid.

Liang Jiahao J, Wang Gang G, Shen Ruile R

Central nervous system nocardiosis is rare and potentially life-threatening, and human infection due to Nocardia amamiensis has seldom been reported; central nervous system involvement in visceral leishmaniasis is likewise uncommon. We report a 69-year-old man who developed progressive impairment of consciousness and coma after recurrent fever. Brain magnetic resonance imaging revealed multiple abscess-like lesions in both cerebral hemispheres, the cerebellum, and the brainstem, accompanied by acute or subacute cerebral infarctions. The cerebrospinal fluid opening pressure was 300 mmH2O. The white blood cell count was 285 × 106/L, with 81.9% polymorphonuclear cells; protein was 1.977 g/L and glucose was 2.34 mmol/L. MetaCAP analysis of cerebrospinal fluid concurrently detected N. amamiensis and L. infantum, and bone marrow smear demonstrated Leishmania amastigotes within macrophages. The patient tested negative for human immunodeficiency virus, and abdominal ultrasonography showed no hepatosplenomegaly. On the available evidence, visceral leishmaniasis was established and central nervous system nocardiosis was strongly suspected. Detection of L. infantum in cerebrospinal fluid supported possible central nervous system involvement, but did not establish a direct contribution to the brain abscess-like lesions. The patient received trimethoprim-sulfamethoxazole, imipenem-cilastatin, amikacin, and liposomal amphotericin B, but his condition continued to deteriorate. He was discharged against medical advice, and follow-up revealed that he had died. This case illustrates that sequencing-based detection is an important clue but cannot replace culture, pathogen-specific polymerase chain reaction, or evidence from lesion tissue.

PubMedBMC pharmacology & toxicology2026-10-14

Correction to: In vitro comparative quality evaluation of different brands of metformin hydrochloride tablets available in Mekelle City, Tigray Regional State, Ethiopia.

Welegebrial Brhane Gebrehiwot BG, Gezae Zenawi Z, Gebrekidan Samrawit Kidanemariam SK, Gebrerufael Gebru Gebremeskel GG et al.

PubMedOpen forum infectious diseases2026-10-14

High Rate of Adverse Events in Patients Receiving Oral Antimicrobials Under a COpAT Monitoring Protocol.

Sawey Ciara C, Burgoyne Colleen C, Winbush Angelina A, Qualls Brandon W BW et al.

We conducted a retrospective review to characterize adverse events in patients receiving oral linezolid, trimethoprim-sulfamethoxazole, voriconazole, and itraconazole monitored under an outpatient parenteral antimicrobial therapy program. Among 118 patients, 61% incurred at least 1 adverse event during treatment, highlighting the need for evidence-based monitoring protocols for complex outpatient antimicrobial therapy.

PubMedAmerican journal of ophthalmology case reports2026-10-14

A case report of ocular nocardiosis secondary to Nocardia asiatica in a patient with acquired immunodeficiency syndrome.

Chen Mike Y MY, Thomas Joanne J, Zhu Catherine C, Mehta Nihaal N et al.

To describe the clinical presentation, diagnosis, management, and outcome of endogenous ocular nocardiosis caused by Nocardia asiatica in a profoundly immunocompromised patient. A 27-year-old man with acquired immunodeficiency syndrome presented with encephalopathy, severe immunosuppression, and innumerable ring-enhancing brain lesions concerning for disseminated opportunistic infection. Ophthalmic examination revealed bilateral subretinal abscesses and deposits without vitreous inflammation, as well as a macula-involving exudative retinal detachment in the right eye. Extensive microbiologic evaluation, including anterior chamber polymerase chain reaction testing, was unrevealing. Progressive neurologic decline prompted craniotomy with brain biopsy, which demonstrated branching filamentous organisms on Grocott methenamine silver staining, with molecular sequencing confirming Nocardia asiatica. Targeted trimethoprim-sulfamethoxazole therapy resulted in systemic and neurologic improvement with consolidation of subretinal lesions. Final visual acuity remained severely limited in the macula-involved right eye but recovered to 20/20 in the left eye. This case represents a detailed report of endogenous ocular nocardiosis attributable to Nocardia asiatica presenting as bilateral subretinal abscesses with multifocal brain involvement. Subretinal abscess-like lesions with minimal intraocular inflammation in the setting of disseminated infection, particularly when accompanied by multifocal brain abscesses, should prompt early consideration of nocardiosis. Early recognition and empiric trimethoprim-sulfamethoxazole therapy may facilitate systemic recovery and preserve vision in less affected eyes.

PubMedDrug metabolism and bioanalysis2026-10-14

Revisiting Cinacalcet HCl Hepatic Disposition: Insights from Isolated Perfused Rat Liver.

Mireskandari Katayoon K, Barazesh Ahmadreza A, Rostamnezhad Mostafa M, Darabi Majid M et al.

Hepatic drug handling determines systemic exposure, yet the balance between tissue uptake, intracellular binding, and metabolic clearance is difficult to dissect in vivo. Cinacalcet hydrochloride (CINA), a calcimimetic used to manage secondary hyperparathyroidism, has low oral bioavailability and is widely described as a high-extraction drug subject to extensive hepatic metabolism. Whether tissue sequestration rather than biotransformation underlies its rapid hepatic removal has not been tested directly in an intact ex vivo liver model. We investigated the hepatic clearance of cinacalcet hydrochloride (CINA) using the isolated perfused rat liver (IPRL) model. A validated high-performance liquid chromatography (HPLC) method was established to quantify CINA and its primary metabolite, M7, in both liver tissue and perfusate samples. To evaluate the influence of perfusate composition and protein binding, experiments were conducted under single-pass perfusion modes, in the presence and absence of bovine serum albumin (BSA). Dose recovery and mass balance analysis indicated that ~93% of the administered dose was recovered: ~63% in liver tissue and ~29% in the outlet perfusate. No metabolites were detected in any sample, pointing to tissue uptake and retention as the dominant clearance mechanism. Drug loss to plastic perfusion tubing was substantial and was only partially offset by BSA. Inclusion of BSA also shifted the apparent drug distribution between liver and perfusate. In the IPRL, hepatic tissue sequestration rather than metabolic conversion was the dominant clearance mechanism for CINA. Non-specific adsorption to plastic perfusion tubing and the protein content of the perfusion medium were important confounders that must be controlled in future ex vivo studies. CINA was extensively retained in rat liver tissue with negligible in situ metabolism over 90 min of single-pass perfusion, raising the question of whether metabolic extraction truly explains its low oral bioavailability in vivo.

PubMedAmerican journal of perinatology2026-10-14

Cyclosporiasis in Pregnancy: A Narrative Review.

Elimian Andrew A, Wei Lili S LS, Canterino Joseph J, Figueroa Reinaldo R

Cyclosporiasis, caused by the protozoan parasite Cyclospora cayetanensis, is an emerging foodborne illness of increasing clinical relevance in both endemic and developed countries. Its specific implications during pregnancy remain poorly characterized. Our objective is to synthesize current evidence on the clinical presentation, diagnosis, treatment, and prevention of cyclosporiasis during pregnancy. This is a narrative review of peer-reviewed literature published between 2012 and 2026, supplemented by guidance from the Centers for Disease Control and Prevention (CDC) and other major health authorities. Cyclosporiasis presents with prolonged watery diarrhea, profound fatigue, and anorexia, all features of heightened concern during pregnancy, given the risks of dehydration, malnutrition, and preterm labor. Trimethoprim-sulfamethoxazole (TMP-SMX) remains the treatment of choice, but its use requires careful consideration of gestational timing, folate supplementation, and the risk of neonatal hyperbilirubinemia. No highly effective alternatives exist for sulfonamide-allergic patients. There is no evidence of vertical transmission. Cyclosporiasis in pregnancy is a clinically challenging condition requiring prompt recognition and tailored management. Prevention through rigorous food and water hygiene is paramount. TMP-SMX can be used safely with appropriate precautions. Further research is needed to define pregnancy-specific outcomes and treatment protocols.

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about trimethoprim hydrochloride